- Fulcrum Therapeutics press release ( NASDAQ: FULC ): Q2 GAAP EPS of -$0.83 misses by $0.17 .
- Revenue of $1.9M (-56.6% Y/Y) misses by $1.06M .
- As of June 30, 2022, cash, cash equivalents, and marketable securities were $169.0M, as compared to $218.2M as of December 31, 2021.
- Based on current operating plans, including successful implementation of the operational realignment, Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into mid-2024.
For further details see:
Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M